Christopher J. Chermansky

Christopher J. Chermansky

Christopher J. Chermansky

Urology

EDUCATION and TRAINING

UNDERGRADUATE:

1982 – 1986: Saint Vincent Colleg Latrobe, PA, BS in 1986:Biology

GRADUATE:

1986-1990: Georgetown University School of Medicine, Washington, D.C., MD in 1990: Dr. William, Maxted Urology

POSTGRADUATE:

Internship:

1990-1991: University of Texas Southwestern Medical Center, Dallas, TX: Dr. C. James Carrico, General Surgery

Residency:

1991-1996: University of Texas Southwestern Medical Center,Dallas, TX: Dr. John D. McConnell, Urology

Fellowship in Neurourology and Female Urology:

2001- 2004: University of Pittsburgh Medical Center, Pittsburgh, PA: Dr. Michael B. Chancellor, Urology

ACADEMIC APPOINTMENTS

  • 2012 – Present: Assistant Professor of Urology at University of Pittsburgh Medical Center
  • 2008 – 2012: Assistant Professor of Urology at Louisiana State University Health Sciences Center in New Orleans
  • 2010 – 2012: Adjunct Assistant Professor of Urology at Tulane University
  • 2002 – 2004: Clinical Instructor in Urology at the University of Pittsburgh

CERTIFICATION and LICENSURE

BOARD CERTIFICATION:

  • Certified Diplomate of the American Board of Urology
    Effective 02/28/2006 – Current
  • Certified Female Pelvic Medicine and Reconstructive Urology
  • Effective 09/2015 – Current

MEDICAL or OTHER PROFESSIONAL LICENSURE:

  • Pennsylvania State Board of Medicine – MD418680: 2003 – Present
  • Louisiana State Board of Medical Examiners – MD202591: 2008 – Present
  • Medical Board of California – A76588: 2001 – Present

MEMBERSHIPS in PROFESSIONAL and SCIENTIFIC SOCIETIES

  • American Urological Association (AUA): 1996 – Present
  • Society of Urodynamics and Female Pelvic Medicine: 2008 – Present and Urogenital Reconstruction (SUFU).
  • International Continence Society (ICS): 2009 – Present
  • American Urogynecologic Society (AUGS): 2014 – Present
  • The Society of University Urologists (SUU): 2010 – Present
  • Northeastern Section of AUA: 2003 – Present
  • Southeastern Section of AUA: 2009 – 2012
  • Louisiana State Medical Society: 2009 – 2010
  • Pennsylvania Medical Society: 2002 – 2007
  • Allegheny County Medical Society: 2002 – 2007
  • Pittsburgh Urological Association: 2003 – 2007
  • Western Section of AUA: 2000 – 2001

HONORS

  • NIH/K12 Physician Scientist Fellowship in Neurourology and Female Urology: 2002

PUBLICATIONS

Refereed Articles:

  1. Takaoka El, Kurobe M, Okada H, Takai S, Suzuki T, Shimizu N, Kwon J, Nishiyama H, Yoshimura N, Chermansky CJ. Effect of TRPV4 activation in a rat model of detrusor underactivity induced by bilateral pelvic nerve crush injury. Neurourol Urodyn. 37:2527-2534, 2018.
  2. Chermansky CJ, Kadow BT, Kashyap M, and Tyagi P. MicroRNAs as potential biomarkers to predict the risk of urinary retention following intradetrusor onabotulinumtoxin-A injection. Neurourol Urodyn. 37:99-105, 2018.
  3. Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, Vasavada SP, Nguyen JN, Wilson TS, Harvie HS, Wallace D; Pelvic Floor Disorders Network. Two-Year Outcomes of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol 74:66-73, 2018.
  4. Tyagi P, Janicki J, Moon CH, Kaufman J, Chermansky C. Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. Int Urol Nephrol. 50:401-409, 2018.
  5. Kashyap M, Pore S, de Groat WC, Chermansky C, Yoshimura N, and Tyagi P. BDNF Overexpression in Bladder Induces Neuronal Changes to Mediate Bladder Overactivity. Am J Physiol Renal Physiol 315:F45-F56, 2018.
  6. Tyagi P, Kashyap M, Yoshimura N, Chancellor M, Chermansky CJ. Past, Present, and Future of Chemodenervation with Botulinum Toxin in the Treatment of OAB. J Urol. 197:982-990, 2017.
  7. Ginsberg DA, Drake MJ, Kaufmann A, Radomski S, Gousse A, Chermansky CJ, Magyar A, Nicandro JP, Nitti VW; 191622-096 investigators. Long-Term Treatment with OnabotulinumtoxinA Results in Consistent, Durable Improvements in Health-Related Quality of Life in Patients with Overactive Bladder. J Urol. 198:897-904, 2017.
  8. Richter HE, Amundsen CL, Erickson SW, Jelovsek JE, Komesu Y, Chermansky C, Harvie HS, Albo M, Myers D, Gregory WT, Wallace D; NICHD Pelvic Floor Disorders Network. Characteristics Associated With Treatment Response and Satisfaction in Women Undergoing OnabotulinumtoxinA and Sacral Neuromodulation for Refractory Urgency Urinary Incontinence. J Urol 198:890-896, 2017.
  9. Ferroni MC, Chaudhry R, Shen B, Chermansky CJ, Cannon GM, Schneck FX, Ost MC, Tai C, and Stephany HA. Transcutaneous Electrical Nerve Stimulation of the Foot: Results of a Novel At-Home, Non-invasive Treatment for Nocturnal Enuresis in Children. Urology 101:80-84, 2017.
  10. Chermansky CJ and Chancellor MB. Use of Botulinum Toxin In Urologic Diseases. Urology 91:21-32, 2016.
  11. Chermansky CJ and Moalli PM. Role of Pelvic Floor in Lower Urinary Tract Function. Auton Neurosci. 200:43-48, 2016.
  12. Tennyson LE, Tai C, and Chermansky CJ. Using the Native Afferent Nervous System to Sense Bladder Fullness: State of the Art. Curr Bladder Dysfunct Rep. 11:346-349, 2016.
  13. Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C, 191622-906 Investigators (including Chermansky CJ). Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5 year study. J Urol. 196:791-800, 2016.
  14. Lee C, Chermansky CJ, and Damaser MS.       Translational approaches to the treatment of benign urologic conditions in elderly women. Curr Opin Urol 26:184-192, 2016.
  15. Chuang YC, Chermansky C, Kashyap M, and Tyagi P.       Investigational drugs for bladder pain syndrome (BPS)/interstitial cystitis (IC). Expert Opin Investig Drugs 25:521-529, 2016.
  16. Argade S, Chermansky C, and Tyagi P. Biomarkers for interstitial cystitis/painful bladder syndrome. Women’s Health 12:87-90, 2016.
  17. Kadow BT, Tyagi P, and Chermansky CJ. Neurogenic Causes of Detrusor Underactivity. Curr Bladder Dysfunct Rep. 10(4):325-331, 2015.
  18. Gill BC, Damaser MS, and Chermansky CJ. Future Perspectives in Bladder Tissue Engineering. Curr Bladder Dysfunct Rep. 10(4):443-448, 2015.
  19. Smith PP, Tyagi P, Kuchel GA, Pore S, Chermansky C, Chancellor M, Yoshimura N, and Levanovich P. Advanced therapeutic directions to treat the underactive bladder. Int Urol Nephrol 2014, Suppl 1:S35-44, 2014.
  20. Tyagi P, Smith PP, Kuchel GA, de Groat WC, Birder LA, Chermansky CJ, Adam RM, Tse V, Chancellor MB, and Yoshimura N.       Pathophysiology and animal modeling of underactive bladder. Int Urol Nephrol 2014, Suppl 1:S11-21, 2014.
  21. Song QX, Chermansky CJ, Birder LA, Li L, and Damaser MS. Brain-derived neurotrophic factor in urinary continence and incontinence. Nat Rev Urol 11:579-588, 2014.
  22. Chen ML, Chermansky CJ, Shen B, Roppolo JR, de Groat WC, and Tai C: Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects. J Urol, 191:1009-1013, 2014.
  23. Chermansky CJ and Winters JC: Complications of Vaginal Mesh Surgery. Curr Opin Urol, 22:287-291, 2012.
  24. Chermansky CJ, Krlin RM, and Winters JC: Selective Management of the Urethra at the Time of Pelvic Organ Prolapse Repair: An Assessment of Postoperative Incontinence and Patient Satisfaction. J Urol, 187:2144-2148, 2012.
  25. Soules K, Winters JC, and Chermansky CJ: Central Compartment and Apical Defect Repair Using Synthetic Mesh. Curr Urol Rep, 13:222-230, 2012.
  26. Chermansky CJ, Krlin RM, Holley TD, Woo HH, and Winters JC. Magnetic resonance imaging following Interstim®: An institutional experience with imaging safety and patient satisfaction. Neurourol Urodyn, 30:1486-1488, 2011.
  27. Koski ME and Chermansky CJ: Does Estrogen Have Any Real Effect of Voiding Dysfunction in Women? Curr Urol Rep, 12:345-350, 2011.
  28. Ogawa T, Sasatomi K, Hiragata S, Seki S, Nishizawa O, Chermansky CJ, Pflug BR, Nelson JB, Chancellor MB, and Yoshimura N: Therapeutic Effects of Endothelin-A Receptor Antagonists on Bladder Overactivity in Rats with Chronic Spinal Cord Injury. Urology, 71:341-345, 2008.
  29. Chermansky CJ and Chancellor MB: Estrogen for Overactive Bladder and Patient Perception of Incontinence. Reviews in Urology, 6:94-95, 2004.
  30. Chermansky CJ, Tarin T, Kwon D, Jankowski RJ, Cannon TW, de Groat WC, Huard J, and Chancellor MB: Intraurethral Muscle Derived Cell Injections Increase Leak Point Pressure in a Rat Model of Intrinsic Sphincteric Deficiency. Urology, 63:780-785, 2004.
  31. Chermansky CJ, Cannon TW, Torimoto K, Fraser MO, Yoshimura N, de Groat WC, and Chancellor MB: A Model of Intrinsic Sphincteric Deficiency in the Rat: Electrocauterization. Neurourol Urodyn., 23:166-171, 2004.
  32. Lu S, Cannon TW, Chermansky C, Pruchnic R, Somogyi G, Sacks M, de Groat WC, Huard J, and Chancellor MB: Muscle-Derived Stem Cells Seeded into Acellular Scaffolds Develop Calcium-Dependent Contractile Activity that is Modulated by Nicotinic Receptors. Urology, 61:1285-1291, 2003.
  33. Chermansky CJ and Chancellor MB: Increasing Awareness and Improving the Care of Urinary Incontinence: Highlights from the World Health Organization 2nd International Consultation on Incontinence July 1-4, 2001, Paris France. Reviews in Urology, 5:22-25, 2003.
  34. Cayan S, Chermansky C, Schlote N, Sekido N, Nunes L, Dahiya R, and Tanagho E: The Bladder Acellular Matrix Graft in a Rat Chemical Cystitis Model: Functional and Histologic Evaluation. J Urol, 168:798-804, 2002.

 

Reviews, invited published papers, monographs, books and book chapters:

  1. Tennyson L and Chermansky CJ: Basic Neuroanatomy and Neurophysiology of the Lower Urinary tract, in Adult and Pediatric Neuromodulation (Gilleran J and Alpert S, eds) Springer, Cham, Switzerland, 2018.
  2. Winters, JC, Togami JM, and Chermansky CJ: Vaginal and Abdominal Reconstructive Surgery for Pelvic Organ Prolapse, in Campbell-Walsh Urology 10th Edition (Wein, AJ, ed) Elsevier, Philadelphia, PA, USA pp. 2069-2114, 2012.
  3. Bedestani A, Chermansky CJ, Ghafar M, and Winters JC: Tests of Urethral Function, in Textbook of Female Urology and Urogynecology, 3rd Edition (Cardozo, L. and Staskin, D. eds.) Informa Healthcare, London, UK, 2010.
  4. Chermansky CJ, Huard J, and Chancellor MB: Gene Therapy Using Muscle Derived Stem Cells,
    in Adult Stem Cells (Turksen, K., ed.), The Humana Press Inc., Totowa, NJ pp. 51-66, 2004.
  5. Chermansky CJ and Chancellor MB: Transdermal Oxybutynin in the Treatment of Overactive Bladder. Today’s Therapeutic Trends, 21: 295-306, 2003.

 

Published Abstracts:

  1. Chermansky C, Moon CH, Kaufman J, Tyagi P. MRI Imaging of Human Bladder Wall Using Intravesical Novel contrast mixture: Applications in Painful Bladder Syndrome/Interstitial Cystitis. Female Pelvic Medicine and Reconstructive Surgery, 24 (Number 5, Suppl 1):S90, 2018.
  2. Chermansky C, Janicki J, Moon CH, Kaufman J, Tyagi P. MRI Imaging of Human Bladder Wall Using Intravesical Novel Contrast Mixture: Applications in Painful Bladder Syndrome/Interstitial Cystitis. Neurourol Urodyn, 37(S5):S110-S111, 2018.
  3. Chermansky C, Rechberger T, Miles-Thomas J, Hale D, Cardozo L, Orejudos A, Patel A, Herschorn S. Can OnabotulinumtoxinA Improve Symptoms and Quality of Life in All Patients with Overactive Bladder, Regardless of Disease Duration or Body Mass Index? Neurourol Urodyn, 37(S5):S219-S220, 2018.
  4. Tyagi P, Janicki J, Moon C, Kaufman J, and Chermansky C. Novel Contrast Mixture Achieves Contrast Resolution of Human Bladder Wall Suitable for T1 Mapping: Applications in Interstitial Cystitis (IC) and Beyond. J Urol, 199(4S):e513-e514, 2018.
  5. Takaoka E, Takai S, Suzuki T, Shimizu N, Kwon J, Okada H, Chermansky C, Miyazaki J, Yoshimura N. Urethral Dysfunction and Therapeutic Effects of a PDE 5 Inhibitor (Tadalafil) in a Rat model of Neurogenic Underactive Bladder Induced by Pelvic Nerve Crush. J Urol, 199(4S):e505, 2018.
  6. Tyagi P, Janicki J, Moon CH, Kaufman J, and Chermansky CJ. T1 Mapping of Human Bladder Wall Using Novel contrast mixture in 3T Scanner: Applications in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC). Neurourol Urodyn, 37(S1):S669-S670, 2018.
  7. Amundsen CL, Wilson TS, Wallace DD, Vasavada SP, Nguyen JN, Myers DL, Komesu YM, Honeycutt AA, Harvie HS, Gregory WT, and Chermansky CJ. Two-year Outcomes of sacral Neuromodulation vs. OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence. Female Pelvic Medicine and Reconstructive Surgery, 23 (Number 5, Supplement 1):S13, 2017.
  8. Dunivan GC, Sussman AL, Jelovsek JE, Sung VW, Andy UU, Ballard A, Jakus-Waldman S, Amundsen CL, Chermansky C, Bann C, and Rogers RG. The Patient Perspective on Pelvic Floor disorders Surgical Adverse Events. Female Pelvic Medicine and Reconstructive Surgery, 23 (Number 5, Supplement 1):S17, 2017.
  9. Chermansky C, Shen B, Okonski J, de Groat WC, and Tai C. Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad Electrodes in Women with OAB: Comparison of Different Stimulation Durations. Female Pelvic Medicine and Reconstructive Surgery, 23 (Number 5, Supplement 1):S17, 2017.
  10. Chermansky C, Wilson TS, Wallace DD, Vasavada SP, Nguyen JN, Myers DL, Komesu YM, Honeycutt AA, Harvie HS, Gregory WT, and Amundsen CL. Two-year Outcomes of sacral Neuromodulation vs. OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence. Neurourol Urodyn, 36(S3):S456-S457, 2017.
  11. Chermansky C, Kadow BT, Kashyap MP, and Tyagi P. Expression of miR221 and miR125b in Bladder Biopsy Predict the Risk of High PVR Following Intradetrusor Onabotulinumtoxin-A Injection: Implications for Clinical Decision Making. J Urol, 197(4S):e1048, 2017.
  12. Chermansky C, Shen B, Okonski J, de Groat WC, and Tai C. Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad electrodes in women with OAB: Comparison of Different Stimulation Durations. J Urol, 197(4S):e1049, 2017.
  13. Takaoka E, Takai S, Suzuki T, Shimizu N, Kwon J, Okada H, Nishiyama H, Yoshimura N, and Chermansky C. The Therapeutic Effect of TRPV4 Activation in the Bladder on Underactive Bladder in Rats with Pelvic Nerve Crush. J Urol, 197(4S):e1148, 2017.
  14. Kashyap M, Chermansky C, Yoshimura N, and Tyagi P. MicroRNA-132 Induces Bladder Hypertrophy and Bladder Overactivity via Downregulation of Acetylcholinesterase. J Urol, 197(4S):e398, 2017.
  15. Richter HE, Amundsen CL, Jelovsek JE, Erickson SW, Komesu Y, Chermansky C, Kadima N, Myers D, Harvie HS, Albo M, Wallace D. Demographic and Clinical Variables Associated with Treatment Response in women undergoing OnabotulinumtoxinA and Sacral Neuromodulation. J Urol, 197(4S):e1047, 2017.
  16. Chermansky C, Shen B, Okonski J, de Groat WC, and Tai C. Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad electrodes in women with OAB: Comparison of Different Stimulation Durations. Neurourol Urodyn, 36(S1):S144-S145, 2017.
  17. Chermansky C, Kadow BT, Kashyap MP, and Tyagi P. MicroRNAs as Potential Biomarkers to Predict Risk of Urinary Retention Following Intradetrusor Onabotulinumtoxin-A Injection. Female Pelvic Medicine and Reconstructive Surgery, 22(Number 5, Supplement 1):S19, 2016.
  18. Chermansky C, Kadekawa K, Okada H, Fraser MO, Tyagi P, and Yoshimura N. Reduced Afferent Sensitivity in the Rat Bilateral Pelvic Nerve Crush Model of Detrusor Underactivity.
    J Urol, 195(4S):e415, 2016.
  19. Chermansky C, Shen B, Shepherd J, Tyagi S, Reese J, de Groat W, and Tai C. Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms in Women. J Urol, 195(4S):e894-e895, 2016.
  20. Argade S, Kashyap M, Chermansky C, Ganabathi K, Okonski J, and Tyagi P. Urinary Matrix Metalloproteinase-9 as a Potential Biomarker for Interstitial Cystitis/Painful Bladder Syndrome.
    J Urol, 195(4S):e954, 2016.
  21. Chermansky C, Kadow B, Kashyap M, and Tyagi P. MicroRNAs as Potential Biomarkers to Predict Risk of Urinary Retention Following Intradetrusor Onabotulinumtoxin-A Injection. Neurourol Urodyn, 35(S1):S11, 2016.
  22. Chermansky C, Shepherd J, Shen B, de Groat W, and Tai C. Electrical Stimulation of Afferent Nerves in the Foot with Transcutaneous Adhesive Pad Electrodes Improves Overactive Bladder Symptoms. Female Pelvic Medicine and Reconstructive Surgery, 21(Number 5, Supplement 1): S38-S39, 2015.
  23. Chermansky C, Chen M, Shen B, Roppolo J, de Groat W, Erickson J, and Tai C. Stimulation of Somatic Afferent Nerves in the Foot Improves Overactive Bladder Symptoms. Neurourol Urodyn, 34(S3):S232-S233, 2015.
  24. Chermansky C, Kadekawa K, Okada H, Fraser MO, Tyagi P, Yoshimura N. Reduced Afferent Sensitivity in the Rat Bilateral Pelvic Nerve Crush Model of Detrusor Underactivity. Neurourol Urodyn, 34(S3):S193-S194, 2015.
  25. Kashyap M, Pore S, de Groat WC, Chermansky CJ, Yoshimura N, and Tyagi P. Investigations into the Mechanistic Link Between Elevated Urine BDNF Levels and Expression of Connexin 43 in Bladder Biopsy of Overactive Bladder Patients. J Urol, 193(4S):e133, 2015.
  26. Kashyap M, Pore S, de Groat WC, Chermansky CJ, Yoshimura N, and Tyagi P. BDNF Overexpression Alters the Phenotype of cholinergic Neurons in Rat Bladder. J Urol, 193(4S):e1108, 2015.
  27. Okada H, Wolfe D, Wechuck J, Goss JR, Majima T, Chermansky CJ, and Yoshimura N. Herpes Simplex Virus Type-1 (HSV-1) Vector-Mediated Gene Therapy of Endomorphin for Bladder Overactivity and Nociception. J Urol, 191(4S):e214, 2014.
  28. Chen M, Chermansky C, Shen B, Roppolo J, de Groat W, and Tai C. Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects. Neurourol Urodyn, 33:174-175, 2014.
  29. Chermansky C, Wu Q, Winters JC, and Fraser M: Dramatic Reduction in Urethral Sphincter Activity following Pelvic Nerve Crush in the Rat. J Urol, 187(4S):e103-e104, 2012.
  30. Chermansky C, Chow D, Wu Q, and Fraser M: A Model of Bladder Hypocontractility in the Rat: Pelvic Nerve Crush. Neurourol Urodyn, 30:233-234, 2011.
  31. Chermansky C, Tarin T, Kwon D, Cannon T, de Groat W, Huard J, and Chancellor M.: Intraurethral Muscle Derived Cell Injections Increase Leak Point Pressure in a Rat Model of Intrinsic Sphincteric Deficiency. Neurourol Urodyn, 22:389-390, 2003.
  32. Cannon T., Conway D., Lu S.H., Xavier M., Fraser M.O., Chermansky, C., de Groat, W., Huard, J., and Chancellor, M.: Leak Point Pressure Testing after Tissue Engineered Sling Placement in a Model of Stress Urinary Incontinence. Neurourol Urodyn, 22:372, 2003.
  33. Cannon, T.W., Xavier, M., O’Leary, M.O., Chermansky, C., Erickson, J., Leng, W., and Chancellor, M.B.: Correlation of Bladder and Sexual Function in Women with Neurological Disabilities. J Urol, 169:374, 2003.
  34. Chancellor, M.B., O’Leary, M.O., Erickson, J., Cannon, T.W. Chermansky, C., Leng, W.W., Smith, C.P.: Successful Use of Bladder Botulinum Toxin Injection to Treat Refractory Overactive Bladder. J Urol, 169:351, 2003.
  35. Cannon, T.W., Conway, D., Lu, S.H., Xavier, M., Fraser, M.O., Chermansky, C., de Groat, W.C., Huard, J., and Chancellor, M.B.: Leak Point Pressure Testing After Tissue Engineered Sling Placement in a Model of Stress Urinary Incontinence. J Urol, 169:350, 2003.
  36. Kim, J.H., Bennett, N., Yoshimura, N., Chermansky, C., Kwon, D.D., Tarin, T., Nelson, J.B., de Groat, W.C., Qu-Peterson, Z., Huard, J., and Chancellor, M.B.: Neurorecovery and Improved Erectile Function Using Muscle Derived Stem Cells (MDSC) in a Model of Post-Radical Prostatectomy Erectile Dysfunction. J Urol, 169:323, 2003.
  37. Lu, S.H., Cannon, T.W., Chermansky, C., Pruchnic, R., Somogyi, G., Sacks, M., de Groat, W.C., Huard, J., and Chancellor, M.B.: Muscle-Derived Stem Cells Seeded Acellular Scaffolds Improves Compliance and Develop Calcium Dependent Contractile Activity that is Modulated by Nicotinic Receptors. J Urol, 169:102, 2003.
  38. Tarin, T.V., Chermansky, C.J., Kwon, D.D., Cannon, T., Huard, J., and Chancellor, M.B.: Periurethral Muscle Derived Stem Cell Injections Increase Leak Point Pressure in a Rat Model of Intrinsic Sphincteric Deficiency. J Urol, 169:96, 2003.
  39. Youssif, M.E., Shiina, H., Shirai, M., Nunes, L., Gleason, C., Chermansky, C., Igawa, M., Dahiya, R., and Tanagho, E.A.: Regeneration of the Bladder Acellular Matrix Graft in a Diabetic Rat Model. J Urol, 169:41, 2003.
  40. Pruchnic, R.J., Huard, J., Chermansky, C., Yoshimura, N., de Groat, W.C., and Chancellor, M.B.: Human Skeletal Muscle-Derived Stem Cells for Improving Neurogenic Bladders. Spinal Cord Med, 25:242, 2002.
  41. Chermansky, C., Lu, S.H., Chung, S., Sellaro, T., Gloeckner, D.C., Huard, J., de Groat, W.C., and Chancellor, M.B.: Muscle-Derived Stem Cells Improve Bladder Compliance for Small Intestinal Submucosa. Spinal Cord Med, 25:234, 2002.
  42. Chermansky, C., Lu, S.H., de Groat, W.C., Somogyi, G., Huard, J., Pruchnic, R., and Chancellor, M.B.: Contractility of Small Intestinal Submucosa and Muscle-Derived Stem Cells. Spinal Cord Med, 25:234, 2002.
  43. Lu, S.H., Chung, S., Sellaro, T., Gloeckner, D., Sacks, M., Huard, J., deGroat, W., Chermansky, C. and Chancellor, M.: Could Muscle-Derived Stem Cells make Small Intestinal Submucosa more Compliant for Bladder Reconstitution? J Urol, 167:58, 2002.
  44. Cayan, S., Chermansky, C., Schlote, N., Sekido, N., Nunes, L., Dahiya, R., and Tanagho, E.: The Bladder Acellular Matrix Graft in a Rat Chemical Cystitis Model: Functional and Histologic Evaluation. J Urol, 167:9, 2002.
  45. Richier, J.C., Kaplan, E.P., Chermansky, C.J., Ewalt, D.H., Lin, V.K., and McConnell, J.D.: Analysis of Type III Collagen mRNA Expression in Human Benign Prostatic Hyperplasia. J Urol, 153:344A, 1995.

PROFESSIONAL ACTIVITIES

HOSPITAL APPOINTMENTS

  1. Attending Physician, UPMC Magee-Womens Hospital, Pittsburgh, PA, 2013-Present and 2003-2004
  2. Attending Physician, UPMC Presbyterian Hospital, Pittsburgh, PA, 2012-Present and 2003-2004
  3. Attending Physician, UPMC Shadyside, Pittsburgh, PA, 2013-Present
  4. Attending Physician, UPMC Mercy, Pittsburgh, PA, 2013-Present
  5. Attending Physician, East Jefferson General Hospital, Metairie, LA, 2009-2012
  6. Attending Physician, Medical Center of Louisiana at New Orleans, New Orleans, LA
    2009-2012
  7. Attending Physician, Tulane University Hospital and Clinic, 2010-2012
  8. Attending Physician, Touro Infirmary, New Orleans, LA, 2009-2012
  9. Attending Physician, Allegheny General Hospital, Pittsburgh, PA, 2004-2008
  10. Attending Physician, The Washington Hospital, Washington, PA, 2004-2008
  11. Attending Physician, UPMC McKeesport, McKeesport, PA, 2007-2008
  12. Attending Physician, David Grant Medical Center, Travis AFB, CA, 1996-1999

EDITORIAL BOARD

Neurourology and Urodynamics: 2017–Present

PEER REVIEWER

  1. Journal of Urology: 2010–Present
  2. Neurourology and Urodynamics: 2009–Present
  3. European Urology: 2018-Present
  4. Urology: 2006–Present
  5. BMC Urology: 2012–Present
  6. Journal of Spinal Cord Medicine: 2003–2004

TEACHING

  1. Invited Lecture, “How to Incorporate Office-Based Procedures into Your Already Busy Practice: OnabotulinumtoxinA”, SUFU at the 2018 AUA Conference, San Francisco CA, May 2018.
  2. Invited Lecture, “Urethral diverticulum and Periurethral Masses”, University of Pittsburgh Division of Urogynecology Fellows Conference, Pittsburgh PA, January 2018.
  3. Invited Lecture, “Neurogenic Bladder Review”, University of Pittsburgh Department of Urology Conference, Pittsburgh PA, August 2017.
  4. Faculty Moderator, “Urodynamics”, University of Pittsburgh Department of Urology Conference, Pittsburgh PA, June 2017.
  5. Faculty Moderator, “SUFU Urodynamics Curriculum”, University of Pittsburgh Division of Urogynecology Fellows Conference, Pittsburgh PA, April 2017.
  6. Invited Lecture, “Current and Future Directions in the Management of Refractory OAB”, University of Pittsburgh Department of Obstetrics and Gynecology and Reproductive Sciences Grand Rounds, Pittsburgh PA, November 2015.
  7. Invited Lecture, “Stem Cell Therapy for Urinary Incontinence”, University of Pittsburgh Department of Urology Grand Rounds, Pittsburgh PA, May2015.
  8. Invited Faculty, “Basic Science Poster Session II”, 2014 Annual Meeting of Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction, Miami FL, February 2015.
  9. Faculty Moderator, “SUFU Urodynamics Curriculum”, University of Pittsburgh Division of Urogynecology Fellows Conference, Pittsburgh PA, February 2015.
  10. Faculty Moderator, “Urethral Diverticulum/Periurethral Masses”, University of Pittsburgh Division of Urogynecology Fellows Conference, Pittsburgh PA, December 2014.
  11. Faculty Moderator, “Mixed Urinary Incontinence”, University of Pittsburgh Division of Urogynecology Fellows Conference, Pittsburgh PA, December 2014.
  12. Invited Moderator and Speaker, “Refractory Overactive Bladder – is this a therapeutic failure or different disease?”, 66th Annual Meeting of the Northeastern Section Meeting of the American Urological Association, Amelia Island FL, November 2014
  13. Invited Workshop Faculty, “Clinical Implications of Lower Urinary Tract Biomechanics”, 44th Annual Meeting of International Continence Society, Rio de Janerio Brazil, October 2014.
  14. Invited Lecture, “Urodynamics Overview”, University of Pittsburgh Division of Urogynecology Conference, Pittsburgh PA, April 2014.
  15. Invited Lecture, “Stem Cell Therapy for Urinary Incontinence”, 2014 Southeastern Section Meeting of the American Urological Association, Hollywood FL, March 2014
  16. Invited Lecture, “Stem Cell Therapy for Neurogenic Bladder”, 2014 Southeastern Section Meeting of the American Urological Association, Hollywood FL, March 2014
  17. Moderated Podium Presentation, ” Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects”, 2014 Annual Meeting of the Society for Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction, Miami FL, February 2014
  18. Invited Faculty, “Basic Science Poster Session II”, 2014 Annual Meeting of Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction, Miami FL, February 2014.
  19. Invited Lecture, “Neurogenic Bladder Review”, University of Pittsburgh Department of Neurology Grand Rounds, Pittsburgh PA, February 2014.
  20. Invited Workshop Faculty, “Clinical Implications of Lower Urinary Tract Biomechanics”, 43rd Annual Meeting of International Continence Society, Barcelona Spain, August 2013.
  21. Invited Lecture, “Urodynamics Overview”, University of Pittsburgh Department of Urology Grand Rounds, Pittsburgh PA, August 2013.
  22. Invited Faculty, “Surgical Management of Stress Urinary Incontinence”, Department of Urology Residents Journal Club, Pittsburgh PA, July 2013.
  23. Invited Faculty, “Update on Botox Therapy”, 2013 Annual Meeting of the Louisiana State Urological Society, Shreveport LA, April 2013.
  24. Invited Lecture, “Neuromodulation for the Treatment of Refractory OAB”, University of Pittsburgh Division of Urogynecology Conference, Pittsburgh PA, April 2013.
  25. Invited Faculty, “Basic Urodynamics”, 2013 Annual Meeting of Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU), New Orleans LA, February 2013.
  26. Invited Lecture, “Post-Prostatectomy Incontinence (PPI): AUS versus Male Sling”, University of Pittsburgh Department of Urology Grand Rounds, Pittsburgh PA, January 2013.
  27. Invited Lecturer, “Neuromodulation for the Treatment of Refractory OAB”, Third Military Medical University Department of Urology, Chongqing, China, October 2012.
  28. Invited Lecturer, “Neuromodulation for the Treatment of Refractory OAB”, Tongi Medical School Department of Urology, Wuhan, China, October 2012.
  29. Invited Speaker, “The Clinical Utility of Botox for the Management of Neuropathic Detrusor Overactivity”, 2012 Annual Meeting of the National Medical Association, New Orleans LA, July 2012.
  30. Invited Speaker, “Neurogenic Bladder Review”, 2012 Annual Meeting of the Texas Urological Society, Austin TX, June 2012.
  31. Invited Faculty, “Basic Urodynamics”, 2012 Annual Meeting of Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction (SUFU), New Orleans LA, March 2012.
  32. Invited Speaker, “Post-Prostatectomy Incontinence (PPI): AUS versus Male Sling”, 2012 Ochsner Edgar Burns Visiting Professorship of Urology, New Orleans LA, January 2012.
  33. Invited Lecturer, “Neuromodulation for the Treatment of Refractory OAB”, Tulane Department of Urology, New Orleans LA, October 2011.
  34. Invited Speaker, “Neuromodulation for the Treatment of Refractory OAB”, 2011 Ochsner Edgar Burns Visiting Professorship of Urology, New Orleans LA, June 2011.
  35. Invited Workshop Faculty, “Approaches to Pelvic Organ Prolapse Surgery”, 40th Annual Meeting of International Continence Society, Toronto Canada, August 2010.
  36. Invited Speaker, “Overview of Bladder Treatments in Urinary Incontinence”, AUA Foundation/SBUR Research Conference, Linthicum MD, August 2010.
  37. Invited Speaker, “Management of Mixed Urinary Incontinence in Women”, East Jefferson Hospital Family Practice Department, Metairie LA, April 2010.
  38. Invited Speaker, “Urodynamic Evaluation of Male Voiding Dysfunction”, 2010 Ochsner Edgar Burns Visiting Professorship of Urology, New Orleans LA, January 2010.
  39. Invited Lecturer, “The Neurophysiology of the Neuropathic Bladder after Spinal Cord Injury”, LSUHSC New Orleans Neuroscience Department Graduate Investigative Neuroscience Course, New Orleans LA, November 2009.
  40. Invited Speaker, “Restoring Bladder Function Through Tissue Engineering”, LSUHSC New Orleans Physiology Department Seminar, New Orleans LA, January 2009.
  41. Invited Speaker, “Complications of Slings in Women”, 2009 Ochsner Edgar Burns Visiting Professorship of Urology, New Orleans LA, January 2009.
  42. Invited Speaker, “The Treatment of Mixed Urinary Incontinence in Geriatric Women”, 2008 Louisiana Geriatrics Society Annual Geriatric Update, Metairie LA, December 2008.
  43. Invited Speaker, “The Treatment of Overactive Bladder”, The Washington County Medical Society, Washington PA, January 2008.
  44. Invited Speaker, “The Treatment of Mixed Urinary Incontinence in Women”, The Washington Hospital Grand Rounds, Washington PA, December 2007.
  45. Invited Speaker, “The Neurogenic Bladder”, Botsford Hospital Division of Urology Residency Program on Voiding Dysfunction, Detroit MI, November 2007.
  46. Invited Speaker, “The State of Art in the Treatment of Overactive Bladder”, The Washington Hospital Grand Rounds, Washington PA, June 2007.
  47. Invited Speaker, “The Neurogenic Bladder”, Allegheny General Hospital Division of Neurology, Pittsburgh PA, April 2007.
  48. Invited Speaker, “BPH and Prostate CA Screening”, University of Pittsburgh School of Nursing Lecture for Nurse Practitioner Students, Pittsburgh PA, March 2007.
  49. Invited Speaker, “The State of Art in the Treatment of Overactive Bladder”, LECOM Primary Care 2007, Findlay Lake NY, March 2007.
  50. Invited Speaker, “The State of Art in the Treatment of the Neurogenic Bladder”, HealthSouth Harmarville Rehabilitation Hospital, Harmarville PA, February 2007.
  51. Invited Speaker, “The State of Art in the Treatment of Overactive Bladder”, Indiana Regional Medical Center, Indiana PA, December 2006.
  52. Invited Speaker, “The State of Art in the Treatment of Overactive Bladder”, Western Pennsylvania Refresher Course, West Middlesex PA, September 2006.
  53. Invited Speaker, “BPH”, The Washington Hospital Grand Rounds, Washington PA, March 2006.
  54. Invited Speaker, “The State of Art in the Treatment of Overactive Bladder”, Allegheny General Hospital Department of Medicine Grand Rounds, Pittsburgh PA, May 2005.
  55. Invited Faculty, “Male Chronic Pelvic Pain Syndrome”, University of Pittsburgh Department of Urology Grand Rounds, Pittsburgh PA, June 2004.
  56. Invited Faculty, “Stress Urinary Incontinence”, Department of Urology Residents Journal Club, Pittsburgh PA, December 2003.
  57. Invited Faculty, “Postprostatectomy Incontinence”, University of Pittsburgh Department of Urology Grand Rounds, Pittsburgh PA, April 2003.
  58. Invited Speaker, “The Periurethral Injection of MDC Increase LPP in ISD Rats”, Engineering Tissue Growth International Conference and Exposition Meeting, Pittsburgh PA, March 2003.
  59. Invited Speaker, “The Periurethral Injection of MDC Increase LPP in ISD Rats”, Dr. Johnny Huard’s Research Meeting, Pittsburgh PA, March 2003.
  60. Invited Faculty, “Interstitial Cystitis”, Department of Urology Residents Journal Club, Pittsburgh PA, March 2003.
  61. Invited Faculty, “Voiding Dysfunction”, University of Pittsburgh 3rd Year Medical Student Surgical Specialties Clerkship, Pittsburgh PA, February 2003.
  62. Invited Speaker, “Periurethral MDSC Injections Increase LPP in ISD Rats”, Dr. William deGroat’s Research Meeting, Pittsburgh PA, January 2003.
  63. Invited Faculty, “Urinary Tract Infections”, University of Pittsburgh 3rd Year Medical Student Surgical Specialties Clerkship, Pittsburgh PA, November 2002.
  64. Invited Speaker, “The Bladder Acellular Matrix Graft: Past and Future Directions”, Dr. William deGroat’s Research Meeting, Pittsburgh PA, February 2002.
  65. Invited Speaker, “The Bladder Acellular Matrix Graft in a Rat Chemical Cystitis Model: Functional and Histologic Evaluation”, International Bladder Symposium, Washington, D.C., March 2001.
  66. Invited Speaker, “Female Stress Urinary Incontinence”, Internal Medicine Staff and Residents, David Grant Medical Center, Travis AFB CA, August 1998.
  67. Invited Speaker, “Treatment Options for Metastatic Prostate Cancer”, Internal Medicine Staff and Residents, David Grant Medical Center, Travis AFB CA, February 1998.
  68. Invited Speaker, “Medical Management of BPH”, Internal Medicine Staff and Residents, David Grant Medical Center, Travis AFB, CA, October 1997.
  69. Invited Speaker, “Preventative Management of Kidney Stone Disease”, Family Practice Staff and Residents, David Grant Medical Center, Travis AFB, CA, September 1997.
  70. Invited Speaker, “Treatment Options for Localized Prostate Cancer”, Family Practice Staff and Residents, David Grant Medical Center, Travis AFB, CA, April 1997.
  71. Invited Faculty, “Impotence”, David Grant Medical Center Outpatient Medicine Symposium, Lake Tahoe, CA, January 1997.
  72. Invited Speaker, “Medical Management of BPH”, Family Practice Staff and Residents, David Grant Medical Center, Travis AFB, CA, November 1996.
  73. Invited Speaker, “Medical Management of BPH”, Westmoreland Hospital Grand Rounds, Greensburg PA, January 1996.

PRESENT RESEARCH

  1. Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial (NCT 03320850) Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation for OAB, Study Site Principal Investigator, 2018-Present.
  2. Double-blind, Placebo-controlled Trial (NCT 01893138) Comparing the Safety and Efficacy of AMDC-USR with Placebo in Female Subjects with Stress Urinary Incontinence, Cook Myosite, study Site Principal Investigator, 2013-Present.
  3. Foot Neuromodulation for Overactive Bladder (OAB), 2014-Present.
  4. Bladder Hypocontractility Model in Rat: Pelvic Nerve Crush, Primary Investigator, 2009-Present.

PAST RESEARCH

  1. Refractory Overactive Bladder: Sacral Neuromodulation v. Botulinum Toxin Assessment (ROSETTA), NIH Pelvic Floor Disorders Network, Investigator, 2013-Present.
  2. Effects of Surgical Treatment Enhanced with Exercise for Mixed Urinary Incontinence (MUI) in Women (ESTEEM), NIH Pelvic Floor Disorders Network, Co-Investigator, 2014-Present.
  3. A Pilot Study To Identify Molecular Signatures Predicting High Post-Void Residual Urine In Urine And Tissue Specimens Of Overactive Bladder Patients, 2014-Present.
  4. BOTOX for the Treatment of Urinary Incontinence due to Neurogenic Detrusor Overactivity in
    Patients with Multiple Sclerosis, Allergan, Prncipal Investigator, 2013-2014.
  5. A Multicenter, Long-term, Follow-up Study of the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Patients with Idiopathic Overactive Bladder with Urinary Incontinence, Allergan, Principal Investigator, 2013-2014.
  6. Single-masked, randomized, multicenter, 2-arm parallel study comparing the safety and effectiveness of Bulkamid® and Contigen® as bulking agents for the treatment of stress urinary incontinence in females, Contura, Principal Investigator, 2010-2011.
  7. Phase 2b, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of Tanezumab (anti-NGF) for the treatment of moderate to severe pain associated with interstitial cystitis/ painful bladder syndrome (IC/PBS), Pfizer, Principal Investigator, 2010.
  8. A study to determine how well patient perception of pad use is associated with the actual degree of incontinence in men with post prostatectomy incontinence and to factors which motivate men to seek treatment for incontinence, sponsored by a grant from the Society for Urodynamics and Female Urology, Co-Investigator, 2009.
  9. Phase 2, 16-week, multicenter, randomized, double-blind, placebo-controlled, parallel group proof of concept study evaluating the efficacy and safety of Tanezumab (anti-NGF) for the treatment of pain associated with interstitial cystitis, Pfizer, Principal Investigator, 2008.
  10. Phase 3b, 12-week, randomized, double-blind, double-dummy, placebo controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of Fesoterodine in comparison to Tolterodine ER in patients with overactive bladder, Pfizer, Principal Investigator, 2007-2008.
  11. Psychometric Validation of the OAB Family Impact Measure, MEDTAP International, 2004-2005.
  12. Role of Peripheral and Spinal Endothelin Mechanisms in the Micturition Reflex of Rats with Cystitis and Detrusor Overactivity, 2003.
  13. Muscle Derived Stem Cell Mediated Therapy for Incontinence (R01-DK55387-01), 2002-2003.
  14. NIH Sponsored Grant: R01-DK51101-05, Regeneration of Functional Smooth Muscle Tissue in the Bladder Acellular Matrix Graft, Co-investigator, 10% effort, 2000-2005.

SERVICE

Committees and Academic Services:

  1. Basic Science Committee Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) 2016-Present
  2. Scientific Committee, American Urogynecologic Society 2017-Present
  3. University of Pittsburgh Department of Urology Education Committee 2013– Present
  4. LSUHSC School of Medicine Research Advisory Committee, New Orleans, LA, 2009-2012
  5. LSUHSC School of Medicine Advisory Committee on Continuing Medical Education, New Orleans, LA, 2008-2012
  6. Residency Education Committee, The Washington Hospital, Washington PA, 2004-2008

Community Service:

  1. Treatment of Urinary Incontinence, People Health Lecture Series, New Orleans, LA, January 17, 2012
  2. Urinary Incontinence in Women, New Orleans Ritz Carlton 2010 Speaker’s Bureau, New Orleans LA, May 2010
  3. Urinary Incontinence in Women, New Orleans Marriott 2010 Speaker’s Bureau, New Orleans, LA, January 2010
  4. Incontinence after Prostate Surgery, Lecture to US TOO Prostate Cancer Support Group, Pittsburgh PA, May 2003
  5. Male ED & Treatments for Sex (and MS), Pittsburgh PA, October 7, 2002
  6. Prostate Health for UPMC Bladder Health Symposium, Pittsburgh, PA, June 11, 2002
  7. Berkeley Free Clinic, Berkeley, CA, 1999-2001